Updating results

1150 results

Sort: Relevance | Date

Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)

Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in people with alcohol dependence

Technology appraisal guidance Published November 2014

Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)

Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

Technology appraisal guidance Published September 2014 Last updated June 2019

Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

Evidence-based recommendations on ipilimumab (YERVOY) for treating previously untreated advanced (unresectable or metastatic) melanoma (skin cancer)

Technology appraisal guidance Published July 2014

Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)

Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention (PCI) for treating acute coronary syndrome (ACS)

Technology appraisal guidance Published July 2014

Canagliflozin in combination therapy for treating type 2 diabetes (TA315)

Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes

Technology appraisal guidance Published June 2014

Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)

Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure

Technology appraisal guidance Published June 2014

Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

Evidence-based recommendations on bortezomib (Velcade) for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell..

Technology appraisal guidance Published April 2014

Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)

Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-TK mutation-positive locally advanced or metastatic non-small-cell lung cancer..

Technology appraisal guidance Published April 2014

Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)

Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis

Technology appraisal guidance Published March 2014

Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)

Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults

Technology appraisal guidance Published April 2016 Last updated July 2016

Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)

Evidence-based recommendations on ruxolitinib (Jakavi) for treating disease-related splenomegaly or symptoms in adults with myelofibrosis

Technology appraisal guidance Published March 2016

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary heterozygous-familial and non-familial hypercholesterolaemia.

Technology appraisal guidance Published February 2016

Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

Technology appraisal guidance Published February 2016

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima…

Technology appraisal guidance Published February 2016

Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)

NICE is unable to make a recommendation about the use in the NHS of Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive…

Technology appraisal guidance Published January 2016

Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)

Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

Technology appraisal guidance Published January 2016

Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) (TA38)

Evidence-based recommendations on inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)

Technology appraisal guidance Published March 2002

Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

Evidence-based recommendations on nintedanib (Ofev) for people with idiopathic pulmonary fibrosis.

Technology appraisal guidance Published January 2016

Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

Evidence-based recommendations on ramucirumab (Cyramza)

Technology appraisal guidance Published January 2016

Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer before chemotherapy is indicated

Technology appraisal guidance Published January 2016

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab…

Technology appraisal guidance Published January 2016

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

Evidence-based recommendations on abatacept, adalimumab, etanercept and tocilizumab for treating polyarticular juvenile idiopathic arthritis (JIA)

Technology appraisal guidance Published December 2015

Bortezomib for previously untreated mantle cell lymphoma (TA370)

Evidence-based recommendations on bortezomib (Velcade) for treating previously untreated mantle cell lymphoma in adults

Technology appraisal guidance Published December 2015

Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)

Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published September 2016

Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)

Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults

Technology appraisal guidance Published August 2016

Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases

Technology appraisal guidance Published August 2016

Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had..

Technology appraisal guidance Published August 2016

Bosutinib for previously treated chronic myeloid leukaemia (TA401)

Evidence-based recommendations on bosutinib (Bosulif) for previously treated chronic myeloid leukaemia in adults

Technology appraisal guidance Published August 2016

Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

Evidence-based recommendations on nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for treating advanced melanoma (skin cancer)

Technology appraisal guidance Published July 2016

Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)

Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia (AML) with more than 30% bone marrow blasts

Technology appraisal guidance Published July 2016

Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

Evidence-based recommendations on lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del..

Technology appraisal guidance Published July 2016

Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397)

Evidence-based recommendations on belimumab (Benlysta) as an add-on treatment for active autoantibody-positive systemic lupus erythematosus

Technology appraisal guidance Published June 2016

Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)

Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma with a BRAF V600 mutation

Technology appraisal guidance Published June 2016

Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia

Technology appraisal guidance Published June 2016

Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia

Technology appraisal guidance Published June 2016

Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

Evidence-based recommendations on adalimumab (Humira) for treating moderate to severe hidradenitis suppurativa (HS) (acne inversa)

Technology appraisal guidance Published June 2016

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)

Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) for treating type 2 diabetes in adults

Technology appraisal guidance Published May 2016

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)

Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx), paclitaxel, trabectedin (Yondelis) and gemcitabine...

Technology appraisal guidance Published April 2016

Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

Evidence-based recommendations on dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant/intolerant chronic myeloid leukaemia in adults

Technology appraisal guidance Published December 2016

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive breast cancer in adults

Technology appraisal guidance Published December 2016

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

Technology appraisal guidance Published December 2016

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy

Technology appraisal guidance Published December 2016

Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events such as heart attacks or stroke after myocardial infarction (MI)

Technology appraisal guidance Published December 2016

Apremilast for treating moderate to severe plaque psoriasis (TA419)

Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published November 2016

Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults

Technology appraisal guidance Published November 2016

Nivolumab for previously treated advanced renal cell carcinoma (TA417)

Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma (RCC/kidney cancer) in adults

Technology appraisal guidance Published November 2016

Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

Evidence-based recommendations on osimertinib (Tagresso) for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer

Technology appraisal guidance Published October 2016

Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)

Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor

Technology appraisal guidance Published October 2016

Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)

Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for unresectable or metastatic melanoma in adults with a BRAF V600

Technology appraisal guidance Published October 2016

Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)

Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C (HCV) in adults

Technology appraisal guidance Published October 2016